A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

LCTX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 28.10%

Insider Buying (Last 12 Months): $7,100,002.00

Insider Selling (Last 12 Months): $0.00

Lineage Cell Therapeutics Insider Trading History Chart

Lineage Cell Therapeutics Share Price & Price History

^$1.15

▼ -0.05 (-4.18%)

As of 04/19/2024 01:00 AM ET

Days: 30 | 90 | 365

Urgent alert: open this for a huge profit potential

From Timothy Sykes | Ad

This groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo, or CNBC.

See Tim’s instructions to make this remarkably simple trade right here

Lineage Cell Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/8/2024	Don M Bailey	Director	Buy	96,155	$1.04	$100,001.20	158,801
2/6/2024	Broadwood Partners, L.P.	Director	Buy	6,730,770	$1.04	$7,000,000.80	41,666,255
3/31/2022	Brian M Culley	CEO	Buy	6,400	$1.53	$9,792.00	97,787
3/28/2022	Dipti Amin	Director	Buy	35,000	$1.63	$57,050.00
3/25/2022	Brian M Culley	CEO	Buy	5,250	$1.38	$7,245.00
3/24/2022	Michael H Mulroy	Director	Buy	7,000	$1.40	$9,800.00
12/28/2021	Gary S Hogge	SVP	Sell	501,588	$2.45	$1,228,890.60
6/29/2021	Angus C. Russell	Director	Sell	4,720	$2.97	$14,018.40	92,220

Urgent alert: open this for a huge profit potential

From Timothy Sykes | Ad

This groundbreaking technology that Tim calls “Inception” isn’t being talked about anywhere… not on Fox, Yahoo, or CNBC.

See Tim’s instructions to make this remarkably simple trade right here

SEC Filings (Institutional Ownership Changes) for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)

62.47% of Lineage Cell Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Lineage Cell Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
4/16/2024	Fifth Third Wealth Advisors LLC	20,000	$30K	0.0%	N/A	0.011%
3/11/2024	Vanguard Group Inc.	8,384,687	$9.14M	0.0%	+0.9%	4.447%
2/15/2024	Barclays PLC	183,292	$0.20M	0.0%	+663.8%	0.105%
2/15/2024	Vanguard Group Inc.	8,384,687	$9.14M	0.0%	+0.9%	4.792%
2/15/2024	Fort Sheridan Advisors LLC	40,931	$45K	0.0%	-51.2%	0.023%
2/14/2024	Royal Bank of Canada	173,917	$0.19M	0.0%	+947.6%	0.099%
2/13/2024	DCF Advisers LLC	94,751	$0.10M	0.1%	+14.5%	0.054%
1/23/2024	Defender Capital LLC.	4,969,675	$5.42M	1.9%	-4.1%	2.840%
1/12/2024	SG Americas Securities LLC	30,889	$34K	0.0%	+61.6%	0.018%
12/18/2023	Vanguard Group Inc.	8,312,332	$9.81M	0.0%	+16.1%	4.750%
12/6/2023	Citigroup Inc.	133,051	$0.16M	0.0%	-16.2%	0.076%
11/24/2023	Deutsche Bank AG	79,094	$93K	0.0%	+622.5%	0.045%
11/15/2023	Laurion Capital Management LP	1,136,471	$1.34M	0.0%	-42.2%	0.649%
11/14/2023	California State Teachers Retirement System	28,475	$34K	0.0%	-33.7%	0.016%
11/13/2023	Connor Clark & Lunn Investment Management Ltd.	182,561	$0.22M	0.0%	-27.9%	0.104%
11/13/2023	Northern Trust Corp	1,203,957	$1.42M	0.0%	+9.1%	0.688%
11/13/2023	LPL Financial LLC	96,000	$0.11M	0.0%	-17.2%	0.055%
11/13/2023	Rathbones Group PLC	35,000	$41K	0.0%	N/A	0.020%
11/9/2023	Deutsche Bank AG	79,094	$93K	0.0%	+622.5%	0.045%
11/9/2023	Citigroup Inc.	133,051	$0.16M	0.0%	-16.2%	0.076%
11/8/2023	HighTower Advisors LLC	54,071	$64K	0.0%	+58.5%	0.031%
10/23/2023	Defender Capital LLC.	5,184,510	$6.12M	2.2%	+1.5%	2.963%
9/21/2023	Barclays PLC	25,905	$36K	0.0%	+87.3%	0.015%
8/21/2023	California State Teachers Retirement System	42,928	$61K	0.0%	N/A	0.025%
8/16/2023	Nuveen Asset Management LLC	515,445	$0.73M	0.0%	N/A	0.295%
8/15/2023	Wells Fargo & Company MN	79,859	$0.11M	0.0%	+196.9%	0.046%
8/15/2023	Goldman Sachs Group Inc.	26,520	$37K	0.0%	-90.5%	0.015%
8/15/2023	Raffles Associates LP	1,597,739	$2.25M	3.0%	+4.0%	0.913%
8/14/2023	State Street Corp	1,938,712	$2.73M	0.0%	+343.1%	1.108%
8/14/2023	Nuveen Asset Management LLC	515,445	$0.73M	0.0%	N/A	0.295%
8/11/2023	Renaissance Technologies LLC	55,900	$79K	0.0%	N/A	0.032%
8/11/2023	BlackRock Inc.	9,012,064	$12.71M	0.0%	+142.9%	5.157%
8/11/2023	State Board of Administration of Florida Retirement System	36,630	$52K	0.0%	N/A	0.021%
8/11/2023	The Manufacturers Life Insurance Company	61,153	$86K	0.0%	N/A	0.035%
8/11/2023	Geode Capital Management LLC	2,420,808	$3.41M	0.0%	+88.8%	1.385%
8/11/2023	JPMorgan Chase & Co.	1,040,487	$1.47M	0.0%	-6.4%	0.595%
8/11/2023	Northern Trust Corp	1,103,132	$1.56M	0.0%	+365.3%	0.631%
8/10/2023	MetLife Investment Management LLC	68,754	$97K	0.0%	N/A	0.039%
8/10/2023	Charles Schwab Investment Management Inc.	363,215	$0.51M	0.0%	+432.7%	0.208%
8/10/2023	Citigroup Inc.	158,771	$0.22M	0.0%	-65.7%	0.091%
8/4/2023	American International Group Inc.	62,114	$88K	0.0%	N/A	0.036%
8/3/2023	Barclays PLC	25,905	$36K	0.0%	+87.3%	0.015%
8/3/2023	Bank of New York Mellon Corp	356,861	$0.50M	0.0%	+403.8%	0.204%
8/2/2023	MAI Capital Management	951,578	$1.34M	0.0%	+123.8%	0.545%
8/1/2023	Fort Sheridan Advisors LLC	83,931	$0.12M	0.0%	+13.5%	0.049%
7/31/2023	LPL Financial LLC	116,000	$0.16M	0.0%	-10.8%	0.068%
7/18/2023	Defender Capital LLC.	5,109,710	$7.20M	2.5%	-0.5%	3.003%
7/10/2023	Trust Co. of Toledo NA OH	35,394	$50K	0.0%	+41.6%	0.021%
6/1/2023	Prelude Capital Management LLC	16,688	$25K	0.0%	N/A	0.010%
5/18/2023	JPMorgan Chase & Co.	1,112,111	$1.67M	0.0%	+2.2%	0.654%
5/16/2023	Susquehanna International Group LLP	816,387	$1.23M	0.0%	+370.2%	0.480%
5/16/2023	Jane Street Group LLC	596,444	$0.90M	0.0%	+322.3%	0.350%
5/16/2023	Squarepoint Ops LLC	32,856	$49K	0.0%	N/A	0.019%
5/16/2023	Geode Capital Management LLC	1,282,000	$1.92M	0.0%	+1.4%	0.753%
5/16/2023	Balyasny Asset Management L.P.	56,362	$85K	0.0%	+137.4%	0.033%
5/15/2023	Schonfeld Strategic Advisors LLC	22,300	$33K	0.0%	N/A	0.013%
5/15/2023	Two Sigma Advisers LP	67,099	$0.10M	0.0%	-24.7%	0.039%
5/15/2023	Fort Sheridan Advisors LLC	73,931	$0.11M	0.0%	-11.9%	0.043%
5/12/2023	BlackRock Inc.	3,709,578	$5.56M	0.0%	-2.0%	2.180%
5/12/2023	Long Focus Capital Management LLC	175,000	$0.26M	0.0%	-18.6%	0.103%
5/12/2023	Bank of America Corp DE	1,443,779	$2.17M	0.0%	+140,208.9%	0.848%
5/12/2023	HRT Financial LP	249,380	$0.37M	0.0%	+1,134.0%	0.147%
5/12/2023	Dimensional Fund Advisors LP	40,449	$61K	0.0%	-16.5%	0.024%
5/12/2023	Charles Schwab Investment Management Inc.	68,183	$0.10M	0.0%	+49.7%	0.040%
5/12/2023	HighTower Advisors LLC	50,116	$75K	0.0%	+46.9%	0.029%
5/11/2023	PFG Investments LLC	20,200	$30K	0.0%	N/A	0.012%
5/11/2023	ExodusPoint Capital Management LP	32,143	$48K	0.0%	N/A	0.019%
5/11/2023	Citigroup Inc.	462,884	$0.69M	0.0%	-3.0%	0.272%
5/10/2023	Summit X LLC	21,925	$33K	0.0%	-26.7%	0.013%
5/10/2023	MAI Capital Management	425,115	$0.64M	0.0%	-6.9%	0.250%
5/10/2023	Connor Clark & Lunn Investment Management Ltd.	241,022	$0.36M	0.0%	-8.0%	0.142%
5/9/2023	Y Intercept Hong Kong Ltd	66,298	$99K	0.0%	N/A	0.039%
5/5/2023	Truist Financial Corp	42,591	$64K	0.0%	N/A	0.025%
5/1/2023	Virtu Financial LLC	17,521	$26K	0.0%	-60.6%	0.010%
4/27/2023	Defender Capital LLC.	5,136,085	$7.70M	2.7%	+0.8%	3.019%
4/27/2023	Simplicity Solutions LLC	48,000	$72K	0.0%	N/A	0.028%
4/20/2023	Strategic Wealth Investment Group LLC	18,553	$47K	0.0%	-41.2%	0.011%
4/18/2023	ETF Managers Group LLC	318,596	$0.48M	0.0%	-10.0%	0.187%
4/4/2023	Trust Co. of Toledo NA OH	25,000	$38K	0.0%	N/A	0.015%
3/23/2023	ETF Managers Group LLC	353,991	$0.41M	0.0%	+7.3%	0.208%
2/15/2023	Jane Street Group LLC	141,245	$0.17M	0.0%	+315.2%	0.083%
2/15/2023	Raffles Associates LP	1,536,946	$1.80M	2.1%	-26.1%	0.904%
2/15/2023	Virtu Financial LLC	44,442	$52K	0.0%	+343.2%	0.026%
2/15/2023	Shay Capital LLC	29,406	$34K	0.0%	N/A	0.017%
2/15/2023	Millennium Management LLC	399,039	$0.47M	0.0%	-21.2%	0.235%
2/15/2023	Morgan Stanley	131,793	$0.15M	0.0%	+110.7%	0.078%
2/15/2023	Man Group plc	102,396	$0.12M	0.0%	N/A	0.060%
2/15/2023	Boothbay Fund Management LLC	74,094	$87K	0.0%	N/A	0.044%
2/14/2023	Susquehanna International Group LLP	173,619	$0.20M	0.0%	+113.8%	0.102%
2/14/2023	683 Capital Management LLC	128,840	$0.15M	0.0%	N/A	0.076%
2/14/2023	Two Sigma Investments LP	30,662	$36K	0.0%	N/A	0.018%
2/13/2023	Wells Fargo & Company MN	26,950	$32K	0.0%	+389.4%	0.016%
2/13/2023	Barclays PLC	28,109	$33K	0.0%	+268.1%	0.017%
2/13/2023	Geode Capital Management LLC	1,264,409	$1.48M	0.0%	+1.1%	0.744%
2/13/2023	JPMorgan Chase & Co.	1,088,579	$1.27M	0.0%	+3.8%	0.640%
2/10/2023	Connor Clark & Lunn Investment Management Ltd.	261,902	$0.31M	0.0%	-9.2%	0.154%
2/10/2023	Advisor Group Holdings Inc.	46,684	$55K	0.0%	+1,944.0%	0.027%
2/9/2023	MAI Capital Management	456,817	$0.53M	0.0%	-12.5%	0.269%
2/9/2023	Citigroup Inc.	477,174	$0.56M	0.0%	+250.9%	0.281%
2/8/2023	Lincoln National Corp	155,700	$0.18M	0.0%	-28.5%	0.092%

Data available starting January 2016

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Today's Range

Now: $1.15

$1.12

$1.23

50 Day Range

MA: N/A

52 Week Range

Now: $1.15

$0.84

$1.61

Volume

1,098,977 shs

Average Volume

960,146 shs

Market Capitalization

$215.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.31

Who are the company insiders with the largest holdings of Lineage Cell Therapeutics?: Lineage Cell Therapeutics' top insider investors include:
Broadwood Partners, LP (Director)
Don M Bailey (Director)
Learn More about top insider investors at Lineage Cell Therapeutics.
Who are the major institutional investors of Lineage Cell Therapeutics?: Lineage Cell Therapeutics' top institutional shareholders include:
Fifth Third Wealth Advisors LLC — 0.01%
Learn More about top institutional investors of Lineage Cell Therapeutics stock.
Which major investors are buying Lineage Cell Therapeutics stock?: During the previous quarter, LCTX stock was purchased by institutional investors including:
Fifth Third Wealth Advisors LLC
During the last year, these company insiders have bought Lineage Cell Therapeutics stock:
Broadwood Partners, LP (Director)
Don M Bailey (Director)
Learn More investors buying Lineage Cell Therapeutics stock.

SHOCKING Crypto Leak…

From Crypto 101 Media | Ad